PR Newswire Clinical TrialsOriginal article
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
Data ReadoutpositiveCRENESSITYPositive
AI Analysis
Summary
Neurocrine Biosciences presented two-year CRENESSITY (crinecerfont) data in pediatric patients with classic congenital adrenal hyperplasia showing durable hormone control, reduced glucocorticoid exposure, and meaningful clinical improvements including BMI and insulin resistance resolution in significant patient populations.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Two-year data demonstrated durable hormone control, reduced glucocorticoid exposure, and meaningful clinical improvements. 60% of overweight/obese patients at baseline experienced clinically meaningful BMI improvements; 61% of insulin-resistant patients at baseline were no longer insulin resistant.
Importance:7/10
Sentiment:
0.75
pediatriccongenital adrenal hyperplasiahormone controlglucocorticoidclinical trial datatwo-year follow-up
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on May 1, 2026 8:05 PM